Easton Pharmaceuticals Announces It Has

TORONTO--(BUSINESS WIRE)--
Easton Pharmaceuticals (OTC-PINK:EAPH - News), a specialty
pharmaceutical company that designs, develops, and markets a premium
array of topically-delivered therapeutic healthcare products announces
it has ordered specialized ingredients from its various suppliers for
the purpose of creating final batches, trial and test samples of its
reformulated Viorra and other recently added portfolio products.

After undergoing an approval process from its suppliers and distributors
of Hyaluronic Acid in Japan and other ingredients from other suppliers,
Easton was recently given the go ahead to be able to order and receive
ingredients in bulk to create final batch trial and test samples
followed by an anticipated marketing program to not only begin selling
its products to the general public in North America, but the expected
re-start of initiatives in various Latin American markets.

As previously announced, the company has reformulated various parts of
its product line starting with its flagship product "Viorra" and its
transdermal delivery system. In addition to Viorra, the company has
introduced three new OTC products which include a topical OTC wound
healing product, a topically applied pain gel and a motion sickness
product, all based around and encompassing Hyaluronic
Acid as its main active ingredient. A specialized form of Hyaluronic
Acid can only be obtained through one producer in Japan with a certain
amount of batches only made a few times a year.

Final packaging, naming rights and labeling are to be introduced very
shortly. This will be followed by the anticipated marketing of the
products on its soon to be revamped website which will coincide with its
corporate name change from Easton to Ashley Biomedical Inc. Easton
Pharmaceuticals believes there exists a demand and substantial
opportunities in not only North America, but in various latin American
and east Asian markets for Viorra and its other products. Easton intends
on delivering sample trial product including final packaging to
potential south latin market distributors through various consultants.
It must then follow an approval protocol which is considered
considerably shorter than in North America.

In other developments, Easton has also entered into discussions with the
owner of a product for a possible 50% purchase of a potential drug,
which presently has patents for the treatment of Female Sexual Arousal
Disorder. This drug encompasses Alprostadil as its main ingredient,
which is an FDA approved product that is a proven and extremely
effective vasodilator. When used with the companies own delivery system,
Easton believes this proposed product can be a very effective potential
drug for the treatment of Female Sexual Arousal Disorder as well an
effective treatment for men, which can be used as an alternative to its
OTC products. Any such products would need to be approved by the FDA
after undergoing rigorous FDA clinical trials. Additional updates on
this initiative to be disclosed as they become available.

About Easton Pharmaceuticals Inc

Easton Pharmaceuticals is a specialty pharmaceutical company that
designs, develops, and markets a premium array of topically-delivered
therapeutic healthcare products, focused on skin and circulatory
conditions that impact a large and expanding number of consumers
including health issues related to female and male sexual dysfunction,
treatment of certain pain, wound healing, scar and stretch marks,
cellulite and varicose veins, the world market for these conditions is
in excess of $10 billion.

The company's updated gel formulation is an innovative and thought to be
unique transdermal delivery system. Easton Pharmaceuticals flagship
product, VIORRA , is an over-the-counter aid for the treatment to
restore and improve vaginal moisture and elasticity which has a very
positive effect on womens sexual desire and arousal, FSAD (Female
Sexual Arousal Disorder) the world market for these female conditions
are in excess of $2 billion. VIORRA is a topical, daily-use
product classified by the FDA as containing Generally Recognized as Safe
ingredients.

For More Information Visit
http://www.eastonpharma.com
http://www.ashleybiomedical.com

Safe Harbor

This news release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 (The
"Act"). In particular, when used in the preceding of discussion, the
words "pleased," "plan," "confident that," "believe," "expect," or
"intent to" and similar conditional expressions are intended to identify
forward-looking statements within the meaning of the Act and are subject
to the safe harbor created by the Act. Such statements are subject to
certain risks and uncertainties and actual results could differ
materially from those expressed in any of the forward-looking
statements. Such risks and uncertainties include, but are not limited
to, market conditions, general acceptance of the company's products and
technologies, competitive factors, the ability to successfully complete
additional or adequate financing and other risks and uncertainties as
stated in the company's financial reports and filings.

Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel:
+1(347) 284-0192
Media and Investor Relations: info@lamindustries.com
& info@ashleybiomedical.com

Easton Pharmaceuticals Inc.
Dragoslav Milanovic, CEO
+1
416-619-0291
+1 347-284-0192
or
Media and Investor
Relations
info@lamindustries.com
info@ashleybiomedical.com

Source: Easton Pharmaceuticals Inc.